ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Landgren on Carfilzomib and Pomalidomide

C. Ola Landgren, MD, PhD
Published: Wednesday, Apr 10, 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.

Landgren says that researchers and physicians in the field of myeloma are fortunate to have recently-approved treatments. Carfilzomib, a second-generation proteasome inhibitor, and pomalidomide, a third-generation immunomodulatory drug, are both oral agents and provide "hope and promise" for patients. Landgren anticipates the trend of developing oral drugs to continue.
 
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.

Landgren says that researchers and physicians in the field of myeloma are fortunate to have recently-approved treatments. Carfilzomib, a second-generation proteasome inhibitor, and pomalidomide, a third-generation immunomodulatory drug, are both oral agents and provide "hope and promise" for patients. Landgren anticipates the trend of developing oral drugs to continue.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x